FINHUB Insights

PFE · Q3 FY25 · Jun 30 – Sep 28, 2025

Pfizer Q3 FY25: where the revenue came from and where it went

Pfizer Q3 FY25: revenue $16.7B (−6% year over year). Net profit $3.5B. Largest cohort US $10.7B. The whole income statement as a sankey diagram from the SEC filing.

Period
Jun 30 – Sep 28, 2025
Reported
Nov 4, 2025 10-Q
Sankey diagram of Pfizer's income statement for Q3 FY25: revenue of $16.7 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$16.7B −6% year over year
Gross profit$12.5B 75% margin
Operating profit$-3.5B -21% margin
Net profit$3.5B 21% margin

The numbers

All figures in billions of U.S. dollars, for Q3 FY25 (period ends Sep 28, 2025).
ItemValueShare of revenueYear over year
Revenue 16.7 100% −6%
US 10.7 64% −11%
International Developed Markets 3.7 22% +8%
International Emerging Markets 2.3 14% +2%
Cost of revenue−4.225%
Gross profit12.575% margin+5pp
SG&A−3.219%+1pp
Other−12.877%+0pp
Operating profit-3.5-21% margin+0pp
Net profit3.521%−4pp
Filing on EDGAR More quarters of PFE

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters